AMLX Earnings & Financial Statements
Amylyx Pharmaceuticals, Inc.
$28.14
+$0.94(+3.46%)
47
Overall
40
Value
50
Tech
52
Quality
Market Cap
$3.41B
Volume
1.47M
52W Range
$10.83 - $41.14
Target Price
$40.82
AMLX earnings and financial statements: Amylyx Pharmaceuticals, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
AMLX Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | - | $87.40M | $380.79M | $22.23M |
| Cost of revenue | - | $5.95M | $25.44M | $2.99M |
| Operating income | -$153.29M | -$314.73M | $38.80M | -$201.34M |
| EBITDA | -$144.16M | -$301.23M | $55.38M | -$200.85M |
| Net income | -$144.74M | -$301.74M | $49.27M | -$198.38M |
| EPS (diluted) | $-1.53 | $-4.43 | $0.70 | $-3.39 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total assets | $332.64M | $193.63M | $517.45M | $391.45M |
| Total liabilities | $27.39M | $28.87M | $84.02M | $50.85M |
| Shareholders’ equity | $305.26M | $164.76M | $433.43M | $340.61M |
| Cash and equivalents | $226.65M | $77.39M | $170.20M | $62.53M |
| Long-term debt | $4.70M | $463.0K | $1.98M | $4.24M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Operating cash flow | -$123.34M | -$167.65M | $11.92M | -$179.87M |
| Capital expenditure | -$138.0K | -$36.36M | -$1.24M | -$2.53M |
| Free cash flow | -$123.48M | -$204.01M | $10.68M | -$182.40M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | AMLX | $28.14 | +3.5% | 1.47M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Amylyx Pharmaceuticals, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW